Literature DB >> 7241091

Immunogenicity and reactogenicity of a highly purified vaccine against tick-borne encephalitis.

C Kunz, F X Heinz, H Hofmann.   

Abstract

Immunogenicity and reactogenicity of a vaccine containing inactivated tick-borne encephalitis virus prepared by continuous flow zonal ultracentrifugation were compared with those of a previously used, less purified vaccine. Antibody response as measured by hemagglutination inhibition (HI) and enzyme-linked immunosorbent assay (ELISA) was 93% after two vaccinations and 100% after a third dose. The zonally purified vaccine impressively reduced the incidence of side reactions. Pyrexia (greater than 37.3 degrees C) was recorded in only 4--10% of the vaccinees almost exclusively after first vaccinations compared to 17--68% with the old type of vaccine. When these results are evaluated according to criteria commonly used in the United States (ie, pyrexia greater than 100 degrees F = 37.8 degrees C), almost no fewer would be recorded. The frequency of systemic side reactions was even lower (statistically significant) after second and third vaccination. This highly purified vaccine therefore represents an effective and well-tolerated means for the immunoprophylaxis of TBE.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7241091     DOI: 10.1002/jmv.1890060202

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden.

Authors:  R Gustafson; B Svenungsson; M Forsgren; A Gardulf; M Granström
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

3.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 4.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

Authors:  T R Kreil; M M Eibl
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Comparative study of infectious and formaldehyde-inactivated tick-borne encephalitis virus particles.

Authors:  I V Krasilnikov; L B Elbert; M K Khanina; S G Sobolev
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

7.  Concomitant infection with tick-borne encephalitis virus and Borrelia burgdorferi sensu lato in patients with acute meningitis or meningoencephalitis.

Authors:  J Cimperman; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; T Avsic-Zupanc; R N Picken; F Strle
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

8.  Monoclonal antibodies to the structural glycoprotein of tick-borne encephalitis virus.

Authors:  F X Heinz; R Berger; O Majdic; W Knapp; C Kunz
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

9.  Comparison of two different enzyme immunoassays for detection of immunoglobulin M antibodies against tick-borne encephalitis virus in serum and cerebrospinal fluid.

Authors:  F X Heinz; M Roggendorf; H Hofmann; C Kunz; F Deinhardt
Journal:  J Clin Microbiol       Date:  1981-08       Impact factor: 5.948

10.  Pathogenesis and immune response of vaccinated and unvaccinated rhesus monkeys to tick-borne encephalitis virus.

Authors:  P Hambleton; J R Stephenson; A Baskerville; C N Wiblin
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.